Gabapentin Tablet
Product Images NDC 71610-778

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71610-778). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 800 mg (71610 0778 53)

Gabapentin USP 800 mg oral tablets packaging label showing 60 tablets. Label includes storage instructions to keep between 20-25 degrees Celsius, keep dry and tightly closed, and keep out of reach of children. Labeler is Aphena Pharma Solutions - Tennessee, LLC, located in Cookeville, TN. The NDC number is 71610-0778-53.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Figure 1 (Image 01)

Line graph depicting mean pain scores over an 8-week period during a 4-week dose titration followed by a 4-week fixed dose period. It compares placebo and gabapentin at 3600 mg/day, showing a greater decrease in mean pain score with gabapentin over time.*

FDA Label Image

Figure 2 (Image 02)

A line graph showing mean pain scores over a 7-week period comparing placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The x-axis represents weeks, including a 3-week dose titration period followed by a 4-week fixed dose period. The y-axis represents mean pain scores from 0 to 10, with placebo maintaining higher scores than both Gabapentin doses throughout the study.*

FDA Label Image

Figure 3 (Image 03)

A bar chart titled "Figure 3. Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies" displaying results from two studies. Study 1 shows proportions for placebo (PBO) at 12% and Gabapentin 3600 mg (GBP 3600) at 29%. Study 2 shows placebo at 14%, Gabapentin 1800 mg at 32%, and Gabapentin 2400 mg at 34%. Statistical significance is noted with ** p < 0.01 and *** p < 0.001.*

FDA Label Image

Image-04 (Image 04)

A formula showing creatinine clearance calculation (CLCr) as [(140 - age in years) × weight in kg] divided by (72 × serum creatinine in mg/dL), multiplied by 0.85 for female patients. The formula is presented in black text on a white background.*

FDA Label Image

Gabapentin Structural Formula (Image 05)

Chemical structure of gabapentin, showing a cyclohexane ring with two substituents: a primary amine group (CH2NH2) and a carboxyl group (CH2CO2H). The diagram depicts the molecular arrangement of this active ingredient.*

FDA Label Image

Image-09 (Image 09)

A scatter plot showing the percentage difference against daily dose in milligrams for Gabapentin tablets. The graph compares data points from three studies labeled a, b, and c across doses of 600, 900, 1200, and 1800 mg, with percentage differences ranging from about 7% to 18%.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.